The iconic rise of Sildenafil presented a significant opportunity for the market, but its patent has ended, creating a challenging landscape. Alternative versions have flooded the arena, diminishing revenues and putting a strain on profit yields. While leading healthcare companies maintain a presence in this sector , the potential remains unclear b